NTLA

Intellia Therapeutics, Inc. Healthcare - Biotechnology Investor Relations →

YES
57.1% BELOW
↓ Approaching Was -54.4% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $28.60
14-Week RSI 49

Intellia Therapeutics, Inc. (NTLA) closed at $12.28 as of 2026-02-02, trading 57.1% below its 200-week moving average of $28.60. This places NTLA in the extreme value zone. The stock is currently moving closer to the line, down from -54.4% last week. The 14-week RSI sits at 49, indicating neutral momentum.

Over the past 461 weeks of data, NTLA has crossed below its 200-week moving average 6 times. On average, these episodes lasted 47 weeks. Historically, investors who bought NTLA at the start of these episodes saw an average one-year return of +315.2%.

With a market cap of $1422 million, NTLA is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -52.1%. The stock trades at 1.9x book value.

Share count has increased 37.0% over three years, indicating dilution.

Over the past 8.9 years, a hypothetical investment of $100 in NTLA would have grown to $84, compared to $334 for the S&P 500. NTLA has returned -1.9% annualized vs 14.5% for the index, underperforming the broader market over this period.

In the past 12 months, corporate insiders have made 2 open-market purchases totaling $2,405,500. Notably, these purchases occurred while NTLA is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.

Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Growth of $100: NTLA vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After NTLA Crosses Below the Line?

Across 6 historical episodes, buying NTLA when it crossed below its 200-week moving average produced an average return of +255.7% after 12 months (median +44.0%), compared to +17.8% for the S&P 500 over the same periods. 50% of those episodes were profitable after one year. After 24 months, the average return was +64.0% vs +30.5% for the index.

Each line shows $100 invested at the moment NTLA crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Insider Buying Activity

2 conviction buys in the past 12 months (purchases over $500K with meaningful position increases).

DateInsiderTitleValueSharesPosition +%
2026-01-05COHEN FREDERICK E. M.D. PH.D.Director$1,402,500150,000+261.1%
2025-08-20CHASE WILLIAM JDirector$1,003,000100,000+288.2%

Historical Touches

NTLA has crossed below its 200-week MA 6 times with an average 1-year return of +315.2% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Apr 2017Aug 20171927.6%+57.7%-11.8%
Oct 2018Jun 20208444.2%-44.1%-38.1%
Jul 2020Aug 202011.8%+696.5%-31.0%
Aug 2020Sep 202011.0%+875.6%-32.2%
May 2022Jun 2022311.0%-9.6%-72.9%
Oct 2022Ongoing173+87.2%Ongoing-75.5%
Average47+315.2%

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of Friday close, 2026-02-02